Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trialRupert Bartsch, Matthias Preusser, Georg Widhalm et al.|Nature Medicine|2022Cited by 395
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastasesRupert Bartsch, Matthias Preusser, Anna S. Berghoff et al.|Neuro-Oncology|2024Cited by 60
Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumabElisabeth Bergen, Rupert Bartsch, Amelie Binter et al.|Therapeutic Advances in Medical Oncology|2021Cited by 32
280P Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trialRupert Bartsch, Matthias Preusser, Anna S. Berghoff et al.|Annals of Oncology|2021Cited by 23
165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trialRupert Bartsch, Matthias Preusser, Anna S. Berghoff et al.|Annals of Oncology|2022Cited by 17